Jürgen Wolf

Active 1984–2026

129
Papers
30,104
Citations
80
h-index
113
i10-index

Citations

Citations per year for Jürgen Wolf1976: 1 citations1984: 1 citations1986: 1 citations1987: 2 citations1988: 1 citations1989: 1 citations1990: 1 citations1991: 2 citations1993: 1 citations1994: 5 citations1995: 2 citations1996: 1 citations1997: 3 citations1998: 5 citations1999: 8 citations2000: 10 citations2001: 10 citations2002: 40 citations2003: 65 citations2004: 51 citations2005: 67 citations2006: 56 citations2007: 52 citations2008: 50 citations2009: 67 citations2010: 72 citations2011: 105 citations2012: 142 citations2013: 245 citations2014: 240 citations2015: 329 citations2016: 486 citations2017: 465 citations2018: 419 citations2019: 1,128 citations2020: 1,217 citations2021: 1,321 citations2022: 1,155 citations2023: 977 citations2024: 1,667 citations2025: 875 citations2026: 21 citations1977–1983: no citations, so these years are not shown1985: no citations, so this year is not shown1992: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,056 citing papers, 26.3% of this breakdownChina: 1,715 citing papers, 11.2% of this breakdownGermany: 1,020 citing papers, 6.6% of this breakdownItaly: 870 citing papers, 5.7% of this breakdownUnited Kingdom: 821 citing papers, 5.3% of this breakdownFrance: 730 citing papers, 4.8% of this breakdownJapan: 634 citing papers, 4.1% of this breakdownSpain: 605 citing papers, 3.9% of this breakdownNetherlands: 461 citing papers, 3% of this breakdownCanada: 450 citing papers, 2.9% of this breakdownSwitzerland: 387 citing papers, 2.5% of this breakdownSouth Korea: 374 citing papers, 2.4% of this breakdown
0%26.3%Other 21.3%

Fields

  • Medicine64.9%
  • Biochemistry, Genetics and Molecular Biology27%
  • Engineering2.7%
  • Immunology and Microbiology1.8%
  • Computer Science1.4%
  • Mathematics0.4%
  • Other1.8%

Topics

  • Lung Cancer Treatments and Mutations10%
  • Lung Cancer Research Studies7.3%
  • Cancer Immunotherapy and Biomarkers5%
  • Cancer Genomics and Diagnostics4.7%
  • Neuroendocrine Tumor Research Advances2.5%
  • Lung Cancer Diagnosis and Treatment2.1%
  • Other68.4%

Coauthors

All papers

Open in search
  1. Sotorasib for Lung Cancers with KRAS p.G12C Mutation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 1,769

  2. Comprehensive genomic profiles of small cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Danila Seidel, Berit Pinther, Philipp Schaub, Christian Becker, Janine Altmüller, Jun Yokota, Takashi Kohno, Reika Iwakawa, Koji Tsuta, Masayuki Noguchi, Thomas Muley, Hans Hoffmann, Philipp A. Schnabel, Iver Petersen, Yuan Chen, Alex Soltermann, Verena Tischler, Chang‐Min Choi, Yong‐Hee Kim, Pierre P. Massion, Yong Zou, Dragana J. Jovanović, Milica Kontić, Gavin Wright, Prudence A. Russell, Benjamin Solomon, Ina Koch, Michael Lindner, Lucia Anna Muscarella, Annamaria la Torre, John K. Field, Marko Jakopović, Jelena Knežević, Esmeralda Castaños‐Vélez, Luca Roz, Ugo Pastorino, O.T. Brustugun, Marius Lund‐Iversen, Erik Thunnissen, Jens Köhler, Martin Schüler, Johan Botling, Martin Sandelin, Montse Sánchez‐Céspedes, Helga B. Salvesen, Viktor Achter, Ulrich Lang, Magdalena Bogus, Peter M. Schneider, Thomas Zander, Sascha Ansén, Michael Hallek, Jürgen Wolf, Martin Vingron, Yasushi Yatabe, William D. Travis, Peter Nürnberg, Christian Reinhardt, Sven Perner, Lukas C. Heukamp, Reinhard Büttner, Stefan A. Haas, Élisabeth Brambilla, Martin Peifer, Julien Sage, Roman K. Thomas - Nature 2015 cited by 2,428

  3. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David Waterhouse, Luis Paz‐Ares - The Lancet 2023 cited by 566

  4. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 482

  5. Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mikhail Akimov, Rebecca S. Heist - New England Journal of Medicine 2020 cited by 997

  6. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

    Authors: , , , , , , , , , , , , , , - The Lancet Oncology 2022 cited by 420

  7. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Karen L. Reckamp, Grace K. Dy, Jürgen Wolf, Benjamin Solomon, Gerald S. Falchook, Kevin Ebata, Michele Nguyen, Binoj C. Nair, Edward Y. Zhu, Luxi Yang, Xin Huang, Elizabeth Olek, S. Michael Rothenberg, Kōichi Goto, Vivek Subbiah - New England Journal of Medicine 2020 cited by 836

  8. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,734

  9. Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kristin Thompson, Wendy Winckler, David J. Kwiatkowski, Bruce E. Johnson, Pasi A. Jänne, Vincent A. Miller, William Pao, William D. Travis, Harvey I. Pass, Stacey Gabriel, Eric S. Lander, Roman K. Thomas, Levi A. Garraway, Gad Getz, Matthew Meyerson - Cell 2012 cited by 1,840

  10. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gregory E. Sims, Yong Yuan, Byoung Chul Cho - New England Journal of Medicine 2024 cited by 210

  11. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Shantanu Banerji, Gad Getz, Kwon-Sik Park, Daniel Rauh, Christian Grütter, Matthias Fischer, Laura Pasqualucci, Gavin Wright, Zoe Wainer, Prudence A. Russell, Iver Petersen, Yuan Chen, Erich Stoelben, Corinna Ludwig, Philipp A. Schnabel, Hans Hoffmann, Thomas Muley, Michael Brockmann, Walburga Engel-Riedel, Lucia Anna Muscarella, Vito Michele Fazio, Harry J.M. Groen, Wim Timens, Hannie Sietsma, Erik Thunnissen, Egbert F. Smit, Daniëlle A.M. Heideman, Peter J.F. Snijders, Federico Cappuzzo, Claudia Ligorio, Stefania Damiani, John K. Field, Steinar Solberg, Odd Terje Brustugun, Marius Lund‐Iversen, Jörg Sänger, Joachim H. Clement, Alex Soltermann, Holger Moch, Walter Weder, Benjamin Solomon, Jean‐Charles Soria, Pierre Validire, Benjamin Besse, Élisabeth Brambilla, Christian Brambilla, Sylvie Lantuéjoul, Philippe Lorimier, Peter M. Schneider, Michael Hallek, William Pao, Matthew Meyerson, Julien Sage, Jay Shendure, Robert C. Schneider, Reinhard Büttner, Jürgen Wolf, Peter Nürnberg, Sven Perner, Lukas C. Heukamp, Paul K. Brindle, Stefan A. Haas, Roman K. Thomas - Nature Genetics 2012 cited by 1,418

  12. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 213

  13. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 149

  14. Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 205

  15. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R. Wilson, Robert C. Doebele - The Lancet Oncology 2019 cited by 537

  16. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

    Authors: , , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 322

  17. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2015 cited by 1,429

  18. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe

    Authors: , , , , , , , , , - Lung Cancer 2021 cited by 201

  19. Evolutionary trajectories of small cell lung cancer under therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clemens Aigner, Thomas Elter, Karin Toepelt, Yon‐Dschun Ko, S Kurz, Christian Grohé, Monika Serke, Katja Höpker, Lars Hagmeyer, Fabian Doerr, Khosro Hekmath, Judith Strapatsas, K Kambartel, Geothy Chakupurakal, Annette Busch, Franz‐Georg Bauernfeind, Frank Griesinger, Anne Luers, Wiebke Dirks, Rainer Wiewrodt, Andrea Luecke, Ernst Rodermann, Andreas Diel, Volker Hagen, K. Severin, Roland T. Ullrich, Hans Christian Reinhardt, Alexander Quaas, Magdalena Bogus, Cornelius Courts, Peter Nürnberg, Kerstin Becker, Viktor Achter, Reinhard Büttner, Jürgen Wolf, Martin Peifer, Roman K. Thomas - Nature 2024 cited by 105

  20. BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 331

  21. Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis

    Authors: , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2017 cited by 405

  22. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 435

  23. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Denis Moro‐Sibilot, Christian Brambilla, Sylvie Lantuéjoul, Nicolas Lemaître, Alex Soltermann, Walter Weder, Verena Tischler, Odd Terje Brustugun, Marius Lund‐Iversen, Åslaug Helland, Steinar Solberg, Sascha Ansén, Gavin Wright, Benjamin Solomon, Luca Roz, Ugo Pastorino, Iver Petersen, Joachim H. Clement, Jörg Sänger, Jürgen Wolf, Martin Vingron, Thomas Zander, Sven Perner, William D. Travis, Stefan A. Haas, Magali Olivier, Matthieu Foll, Reinhard Büttner, D. Neil Hayes, Élisabeth Brambilla, Lynnette Fernandez‐Cuesta, Roman K. Thomas - Nature Communications 2018 cited by 373

  24. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Grohé, Anna Eisert, Rieke Frank, Leonie Gogl, Carsten Schaepers, Alessandra Holzem, Martin Hellmich, Roman K. Thomas, Martin Peifer, Martin L. Sos, Reinhard Büttner, Jürgen Wolf - Journal of Thoracic Oncology 2018 cited by 259